PODD · 8-K · 20260805PR000167

Regulatory Approval Milestones

INSULET CORP · 2026-08-05 · Importance 53 · Surprise 60

Insulet recorded estimated warranty costs associated with voluntary medical device corrections issued in March and May 2026. The corrections generated $21.9 million of gross-profit costs and $25.0 million of adjusted EBITDA costs in the second quarter, and $33.6 million of gross-profit costs for the six months ended June 30, 2026. The six-month impact exceeded the company’s $24 million materiality threshold and reflects compliance-related costs tied to the corrections.